ChiCTR2000039315 版本V1.5 版本创建时间2020/10/23 15:07:48 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039315 

最近更新日期:

Date of Last Refreshed on:

2020-10-23 15:04:44 

注册时间:

Date of Registration:

2020-10-23 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

评价脑部电阻抗断层成像仪筛查脑部幕上肿瘤的准确性临床试验方案

Public title:

A clinical trial protocol to evaluate the accuracy of brain electrical impedance tomography in screening for supratentorial tumors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

评价脑部电阻抗断层成像仪筛查脑部幕上肿瘤的准确性临床试验方案

Scientific title:

A clinical trial protocol to evaluate the accuracy of brain electrical impedance tomography in screening for supratentorial tumors

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡旺露 

研究负责人:

张建民 

Applicant:

Hu Wanglu 

Study leader:

Zhang Jianmin 

申请注册联系人电话:

Applicant telephone:

+86 19858118860

研究负责人电话:

Study leader's telephone:

+86 13805722695

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

huwanglu123@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zjm135@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市上城区解放路88号浙江大学医学院附属第二医院神经外科

研究负责人通讯地址:

浙江省杭州市上城区解放路88号浙江大学医学院附属第二医院神经外科

Applicant address:

Department of Neurosurgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd, Hangzhou, China

Study leader's address:

Department of Neurosurgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd, Hangzhou, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属第二医院

Applicant's institution:

The Second Affiliated Hospital of Zhejiang University School of Medicine

研究负责人所在单位:

电阻抗断层成像

Affiliation of the Leader:

The Second Affiliated Hospital of Zhejiang University School of Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2019)伦审械第(262)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属第二医院人体研究伦理委员会

Name of the ethic committee:

Human Body Research Ethics Committee of the Second Affiliated Hospital of Zhejiang University Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2019-08-26 00:00:00

伦理委员会联系人:

陈泽鑫

Contact Name of the ethic committee:

Chen Zexin

伦理委员会联系地址:

浙江省杭州市解放路88号

Contact Address of the ethic committee:

88 Jiefang Road, Hangzhou, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属第二医院

Primary sponsor:

The Second Affiliated Hospital of Zhejiang University School of Medicine

研究实施负责(组长)单位地址:

浙江省杭州市解放路88号

Primary sponsor's address:

88 Jiefang Road, Hangzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属第二医院

具体地址:

解放路88号

Institution
hospital:

The Second Affiliated Hospital of Zhejiang University School of Medicine

Address:

88 Jiefang Road, Shangcheng District

经费或物资来源:

自筹经费

Source(s) of funding:

Self financing

Target disease:

Brian tumor

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

与MRI/CT比较,评价脑部电阻抗断层成像仪筛查脑部幕上肿瘤的准确性。  

Objectives of Study:

Compared with MRI, evaluate the accuracy of brain electrical impedance tomography in screening brain supratentorial tumors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 18岁≤年龄≤70岁,男女不限;
2) 已被MRI等常规方法确诊脑部幕上肿瘤的术前患者或健康人群,各23例;
3) 脑肿瘤最长径≥3厘米;
4) 已签署《知情同意书》。
5) 必须是已剃发患者。
6) 人员沟通顺畅。

Inclusion criteria

1) 18 years old <= age <= 70 years old, no gender limit;
2) Preoperative patients or healthy people who have been diagnosed with supratentorial tumors of the brain by conventional methods such as MRI/CT, 23 cases each;
3) The longest diameter of brain tumor is >= 3 cm;
4) The "Informed Consent" has been signed.
5) Must be a shaved patient.
6) Staff communication is smooth.

排除标准:

1) 有全身严重复合伤或失血性休克者;
2) 患有癫痫,中毒症状者;
3) 病情危重者;
4) 脑部有创口或急性炎症的患者;
5) 哺乳期,妊娠期妇女;
6) 无知情同意能力或不能自行签字者;
7) 研究者认为不宜参加本次临床试验的患者。

Exclusion criteria:

1) Those with serious compound injuries or hemorrhagic shock;
2) People with symptoms of epilepsy or poisoning;
3) Critically ill;
4) Patients with wounds or acute inflammation in the brain;
5) Women during lactation and pregnancy;
6) Those who have no informed consent ability or cannot sign by themselves;
7) Patients who the investigator thinks are not suitable to participate in this clinical trial.

研究实施时间:

Study execute time:

From 2020-05-29 00:00:00 To 2021-05-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-05-29 00:00:00 To 2021-05-29 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

MRI/CT

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

MRI/CT

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

脑部电阻抗断层成像仪

Index test:

Brain electrical impedance tomography.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

脑部幕上肿瘤的术前患者

例数:

Sample size:

23

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Preoperative patients who have been diagnosed with supratentorial tumors of the brain.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

健康人群

例数:

Sample size:

23

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Healthy people

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China 

Province:

Zhejiang 

City:

Hangzhou 

单位(医院):

浙江大学医学院附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of Zhejiang University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脑电阻抗

指标类型:

主要指标

Outcome:

Cerebral electrical impedance

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

准确性

指标类型:

主要指标

Outcome:

accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

脑电阻抗

组织:

头颅

Sample Name:

cerebral electrical impedance

Tissue:

Brain

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

non-randomized

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan (www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan (www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表、电子数据采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, Electronic Data Capture(EDC)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-10-23 14:56:23